NAD+ is central to cellular metabolism. That part is not controversial. The cleaner internet story, that everyone loses roughly half of it by middle age and simply needs to put it back, is much harder to defend.
The more useful story is better science anyway.
NAD+, or nicotinamide adenine dinucleotide, is a coenzyme used throughout the body. It participates in the redox reactions that move energy through metabolism and also serves as a substrate for enzyme systems involved in DNA repair, cellular stress response, and signaling. Researchers care about it because it sits at several important intersections of cell biology, not because one blood test can summarize aging.
What NAD+ actually does
In energy metabolism, NAD+ accepts electrons and becomes NADH. Those electrons ultimately feed into the processes cells use to produce ATP. NAD+ is therefore part of the chemistry of energy production, but that does not mean more NAD+ automatically translates into more perceived energy in a healthy person.
NAD+ is also consumed by several enzyme families that have made it central to aging research.
Sirtuins use NAD+ in reactions involved in gene regulation, metabolic adaptation, circadian biology, and cellular stress response.
Sirtuins (SIRT1–SIRT7) are a class of NAD+-dependent deacylase enzymes that regulate gene expression, mitochondrial biogenesis, circadian rhythm, and cellular stress response. Research published in PMC (NIH) describes sirtuins as key mediators of metabolic homeostasis, with SIRT1 in particular governing the interplay between NAD+ biosynthesis and circadian clock function. When NAD+ is insufficient, sirtuin activity falls. And with it, the downstream signaling that keeps cells functioning in an organized, well-regulated way.
PARP enzymes (poly-ADP ribose polymerases) are the primary responders to DNA strand breaks. When DNA is damaged by oxidative stress, radiation, or normal replication errors, PARP enzymes consume NAD+ to initiate repair. The problem is that chronic low-grade DNA damage, which increases with age, keeps PARPs in a state of perpetual activation, steadily depleting the NAD+ pool. As research on NAD+ metabolism and aging in PMC documents, this PARP-driven consumption is one of the primary drivers of the age-associated NAD+ decline.
These are real mechanisms. They explain why NAD+ availability matters inside a cell. They do not, by themselves, prove that raising NAD+ with a supplement or injection will improve longevity, cognition, recovery, or energy in an individual patient.
Does NAD+ decline with age?
Sometimes, depending on what tissue you measure. That qualifier matters.
On the production side, the efficiency of the NAD+ salvage pathway, the primary recycling mechanism, regulated by an enzyme called NAMPT (nicotinamide phosphoribosyltransferase), diminishes with age. NAMPT activity, as documented in NIH research, is critical for the conversion of nicotinamide back to NAD+. As NAMPT function declines, the cell becomes less capable of regenerating the NAD+ it uses.
On the consumption side, the drivers above — sirtuin activity competing for substrate and PARP enzymes responding to increased DNA damage — both accelerate. The pool is being drained faster, and refilled more slowly.
So the responsible conclusion is not that NAD+ never changes with age. It is that the magnitude and meaning of the change appear to depend on tissue, health status, activity, and how NAD+ is measured. There is no single defensible percentage decline that can be applied to every adult from thirty to sixty.
Why researchers still care
The disagreement over a universal age curve does not make NAD+ unimportant. It makes the question more specific.
- Reduced mitochondrial efficiency. Cells have less capacity to generate ATP, manifesting as fatigue, reduced exercise tolerance, and slower recovery from physical and cognitive demands.
- Blunted sirtuin signaling. SIRT1 and its family members regulate hundreds of gene targets involved in inflammation, metabolism, and stress resistance. Reduced sirtuin activity has been associated in preclinical models with accelerated features of aging at the tissue level, as reviewed in the NAD+ and sirtuins in aging literature.
- Disrupted circadian regulation. SIRT1 and NAMPT are deeply intertwined with circadian clock function. Declining NAD+ levels may contribute to the fragmented sleep architecture and circadian drift frequently observed in older adults.
- Increased oxidative burden. NAD+ participates in cellular redox balance. Its depletion shifts cells toward a more oxidized state, amplifying the oxidative stress that accelerates cellular senescence.
What has not been established is the much larger consumer claim: that a low NAD+ state is the hidden cause of ordinary fatigue, brain fog, slower recovery, or aging itself in an otherwise healthy person. Those outcomes are influenced by many systems, and mechanism should not be promoted to diagnosis.
None of these processes operates in isolation. They form a mutually reinforcing cascade. Which is precisely why NAD+ decline is considered by many longevity researchers to be one of the more consequential biochemical changes associated with aging.
Can NAD+ levels be raised?
Yes, at least by some measures. The more difficult question is what that means clinically.
Human trials of oral NAD+ precursors such as nicotinamide riboside and nicotinamide mononucleotide have shown that supplementation can increase NAD+-related metabolites or circulating NAD+ measures. Those trials are useful proof that the pathway can be influenced in humans.
Direct NAD+ infusion represents a more direct approach. Rather than relying on the biosynthetic pathway. Which may itself be compromised in aging. Intravenous or subcutaneous administration delivers NAD+ directly into circulation, allowing for more predictable elevation of systemic levels. Clinician-supervised protocols using injectable NAD+ have been employed in clinical settings for metabolic support, cognitive function, and recovery applications. As pharmacokinetic research on intravenous NAD+ notes, the injectable route bypasses the absorption variability and first-pass metabolism limitations of oral precursors.
Direct injectable NAD+ is an even more emerging part of the conversation. Subcutaneous and intravenous use exist in clinical practice, but the human evidence base for meaningful outcomes in healthy adults is far thinner than the marketing around injectable NAD+ often suggests. There are no large randomized trials establishing injectable NAD+ as a longevity treatment.
Where clinician-supervised NAD+ fits
At AnthologyRX, compounded NAD+ is treated as an emerging prescription option, not as a proven anti-aging intervention.
A licensed clinician reviews the reason you are considering it, your medical history, medications, and the larger health picture before deciding whether a compounded prescription is appropriate. The fact that NAD+ is endogenous and biologically important does not guarantee that adding more produces a particular result.
That distinction is the entire point of medical supervision. Interesting biology can justify a serious conversation without being inflated into a guaranteed outcome.
Compounded NAD+ is not an FDA-approved drug product. It is prepared to an individual prescription by a licensed US pharmacy when a licensed provider determines it is appropriate.
The strongest case for reading about NAD+ is not that aging can be reduced to one depleted molecule. It is almost the opposite. NAD+ is a useful window into how interconnected cellular metabolism, repair, activity, and aging biology actually are.
If you are ready to explore what a clinician-supervised protocol might look like for you, start here.
